Biocon subsidiary to Invest USD 56 Million in Syngene USA Inc for Biologics Facility Acquisition; DIIs increased their stake in last Quarter Biocon subsidiary to Invest USD 56 Million in Syngene USA Inc for Biologics Facility Acquisition; DIIs increased their stake in last Quarter With a PE ratio of 57.6x, the company trades at a premium compared to the industry PE of 46x. The company has ROCE of 14.7 per cent and ROE of 13.2 per cent. Prajwal Wakhare / Tuesday, March 11, 2025 0 45 Article rating: 5.0 Read more